Betulinic Acid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Betulinic Acid
Accession Number
DB12480
Description

Betulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 456.711
Monoisotopic: 456.360345406
Chemical Formula
C30H48O3
Synonyms
  • beta-betulinic acid
External IDs
  • ALS-357
  • NSC-113090

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Betulinic Acid.
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Betulinic Acid.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Betulinic Acid.
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Betulinic Acid.
AminophenazoneThe risk or severity of adverse effects can be increased when Aminophenazone is combined with Betulinic Acid.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Betulinic Acid.
AntrafenineThe risk or severity of adverse effects can be increased when Antrafenine is combined with Betulinic Acid.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Betulinic Acid.
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Betulinic Acid.
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Betulinic Acid.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as triterpenoids. These are terpene molecules containing six isoprene units.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Triterpenoids
Direct Parent
Triterpenoids
Alternative Parents
18-hydroxysteroids / Oxosteroids / Secondary alcohols / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
18-hydroxysteroid / 18-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Cyclic alcohol / Hydrocarbon derivative / Hydroxysteroid
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
hydroxy monocarboxylic acid, pentacyclic triterpenoid (CHEBI:3087) / Lupanes (C08619) / Lupane triterpenoids (LMPR0106140004)

Chemical Identifiers

UNII
4G6A18707N
CAS number
472-15-1
InChI Key
QGJZLNKBHJESQX-FZFNOLFKSA-N
InChI
InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1
IUPAC Name
(1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-17-hydroxy-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0²,¹⁰.0⁵,⁹.0¹⁴,¹⁹]henicosane-5-carboxylic acid
SMILES
[H]OC(=O)[C@]12CC[C@@]([H])(C(C)=C)[C@]1([H])[C@@]1([H])CC[C@]3([H])[C@@]4(C)CC[C@]([H])(O[H])C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC2

References

General References
Not Available
Human Metabolome Database
HMDB0030094
KEGG Compound
C08619
PubChem Compound
64971
PubChem Substance
347828718
ChemSpider
58496
BindingDB
23208
ChEBI
3087
ChEMBL
CHEMBL269277
ZINC
ZINC000004097714

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentEpidermolysis Bullosa1
3CompletedTreatmentWounds2
1Unknown StatusTreatmentMelanoma1
1, 2SuspendedTreatmentDysplastic Nevus Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
GelTopical80 mg/g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000204 mg/mLALOGPS
logP5.34ALOGPS
logP6.64ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)4.75ChemAxon
pKa (Strongest Basic)-0.84ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity132.63 m3·mol-1ChemAxon
Polarizability54.64 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-004i-0019400000-d634f687c0b20b3bf518
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-004i-0019400000-946b3acbf03ebc325984
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-06vi-0009700000-133d884e7fe1aabfb659
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-06vr-0019800000-a2c226a96551460f31b8
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0a4i-0000411190-9e794d71d8e215a3ef7f
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0a4i-0000511290-00b42fd32f4bea1aac24
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0009100000-02c4ffe35137e2459ef9
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0009100000-b369b92782bf0058f776
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0udi-0000900000-31877b3328749253f478
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0udi-0000900000-46226c91dca257ecbdbe
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0119300000-d165dda7f84c911bb084
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0119400000-c8efa7eb386af139bbbb
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0udi-0000900000-5daf110b6535ef5e1cba
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0udi-0000900000-1a6ea554c157db014b7c
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-01p9-0000900000-95cc62b5cf4bd28b6108
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-01p9-0000900000-1a328cc168bc37caf6d7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4r-0920300000-e3035523b40f714793c7

Drug created on October 20, 2016 16:33 / Updated on June 12, 2020 10:53